Zyceva 150 Tablet contains Erlotinib 150 mg, a potent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used primarily in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. Erlotinib acts by selectively inhibiting the intracellular phosphorylation of EGFR, thereby blocking downstream signaling pathways involved in tumor cell proliferation, survival, and metastasis. Zyceva 150 is indicated for patients with locally advanced or metastatic NSCLC who have demonstrated EGFR mutations and for use in combination with gemcitabine in patients with locally advanced, unresectable, or metastatic pancreatic cancer. The tablet is administered orally, typically once daily, and should be taken on an empty stomach to optimize absorption. Common adverse effects include rash, diarrhea, anorexia, and fatigue, with interstitial lung disease and hepatotoxicity being rare but serious potential complications. Regular monitoring of liver function tests and clinical assessment for pulmonary symptoms is recommended during therapy. Dose adjustments may be necessary based on toxicity severity. Zyceva 150 should be prescribed under oncological supervision, considering potential drug interactions and contraindications. This targeted therapy offers improved progression-free survival in selected patient populations, representing a significant advancement in personalized cancer treatment.